PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsMupirocin
Mupirocin
Centany, Mupirocin (mupirocin) is a small molecule pharmaceutical. Mupirocin was first approved as Bactroban on 1987-12-31. It is used to treat bacterial infections and impetigo in the USA.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Centany, Mupirocin (discontinued: Bactroban, Mupirocin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mupirocin
Tradename
Company
Number
Date
Products
CENTANYPadagisN-050788 RX2002-12-04
1 products
Show 1 discontinued
Mupirocin calcium
Tradename
Company
Number
Date
Products
BACTROBANGSKN-050703 DISCN1995-09-18
1 products, RLD
BACTROBANGSKN-050746 DISCN1997-12-11
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bactrobanNew Drug Application2012-10-24
centany2007-02-13
dermacinrx clorhexacinunapproved drug other2024-12-13
dermawerx surgical plus pakANDA2015-12-09
levocetirizine dihydrochloride 2% / mupirocin 2% / triamcinolone acetonide 0.025%unapproved drug other2019-05-14
lidocaine 2% / mupirocin 2%unapproved drug other2019-05-14
metronidazole 1% / mupirocin 2% /unapproved drug other2019-05-14
metronidazole 1% / mupirocin 2%unapproved drug other2019-05-14
mupirocinANDA2025-09-26
nusurgepak surgical prep/carepakANDA2020-06-22
Show 2 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infections—D001424A49
impetigoEFO_1000714D007169L01
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX09: Mupirocin
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AX: Other nasal preparations in atc
— R01AX06: Mupirocin
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544————213
Communicable diseasesD003141—————213
Staphylococcal infectionsD013203—A49.01———213
Hiv infectionsD015658EFO_0000764B20———1—1
Acquired immunodeficiency syndromeD000163EFO_0000765B20———1—1
Staphylococcus aureusD013211NCBITaxon_1280————1—1
Cross infectionD003428—————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CellulitisD002481EFO_0003035L03.90————22
Wound healingD014945GO_0042060—————11
Bacterial infectionsD001424—A49————11
Infectious skin diseasesD012874——————11
Bacterial skin diseasesD017192——————11
ImpetigoD007169EFO_1000714L01————11
Community-acquired infectionsD017714——————11
AbscessD000038EFO_0003030—————11
FolliculitisD005499——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMupirocin
INNmupirocin
Description
Mupirocin is an alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. It has a role as a bacterial metabolite, an antibacterial drug and a protein synthesis inhibitor. It is a monocarboxylic acid, a member of oxanes, an epoxide, a secondary alcohol, a triol and an alpha,beta-unsaturated carboxylic ester. It is a conjugate acid of a mupirocin(1-).
Classification
Small molecule
Drug classt-RNA synthetase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
Identifiers
PDB—
CAS-ID12650-69-0
RxCUI—
ChEMBL IDCHEMBL719
ChEBI ID7025
PubChem CID446596
DrugBankDB00410
UNII IDD0GX863OA5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mupirocin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,052 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,427 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use